GeneDx Holdings Corp.

Equities

WGS

US81663L2007

Healthcare Facilities & Services

Market Closed - Nasdaq 13:00:00 2024-07-03 EDT 5-day change 1st Jan Change
28 USD +0.86% Intraday chart for GeneDx Holdings Corp. +6.91% +918.18%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
GeneDx Holdings Corp.(NasdaqGS:WGS) added to Russell Small Cap Comp Value Index CI
GeneDx Holdings Corp.(NasdaqGS:WGS) added to Russell Small Cap Completeness Index CI
GeneDx Holdings Corp.(NasdaqGS:WGS) added to Russell Microcap Growth Index CI
GeneDx Holdings Corp.(NasdaqGS:WGS) added to Russell 3000 Value Index CI
GeneDx Holdings Corp.(NasdaqGS:WGS) added to Russell 2000 Index CI
GeneDx Holdings Corp.(NasdaqGS:WGS) added to Russell 3000E Index CI
GeneDx Holdings Corp.(NasdaqGS:WGS) added to Russell 2500 Value Index CI
GeneDx Holdings Corp.(NasdaqGS:WGS) added to Russell Microcap Index CI
GeneDx Holdings Corp.(NasdaqGS:WGS) added to Russell 2500 Growth Index CI
GeneDx Holdings Corp.(NasdaqGS:WGS) added to Russell 3000E Growth Index CI
GeneDx Holdings Corp.(NasdaqGS:WGS) added to Russell 3000 Growth Index CI
GeneDx Holdings Corp.(NasdaqGS:WGS) added to Russell 2000 Value Index CI
GeneDx Holdings Corp.(NasdaqGS:WGS) added to Russell 2000 Growth Index CI
GeneDx Holdings Corp.(NasdaqGS:WGS) added to Russell 2000 Dynamic Index CI
GeneDx Holdings Corp.(NasdaqGS:WGS) added to Russell Microcap Value Index CI
GeneDx Holdings Corp.(NasdaqGS:WGS) added to Russell Small Cap Comp Growth Index CI
GeneDx Holdings Corp.(NasdaqGS:WGS) added to Russell 2500 Index CI
GeneDx Holdings Corp.(NasdaqGS:WGS) added to Russell 3000 Index CI
GeneDx Holdings Corp.(NasdaqGS:WGS) added to Russell 3000E Value Index CI
BTIG Adjusts Price Target on GeneDx Holdings to $35 From $19, Maintains Buy Rating MT
Transcript : GeneDx Holdings Corp. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 03:20 PM
GeneDx Partners With Epic to Expand Access to Testing Services in Neonatal ICUs MT
GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients CI
GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients CI
Health Care Flat Amid Mixed Earnings -- Health Care Roundup DJ
Chart GeneDx Holdings Corp.
More charts
GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Company's segments are GeneDx inclusive of Legacy GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. GeneDx utilizes an integrated portfolio of laboratory processes, software tools, and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. GeneDx provides a variety of genetic diagnostic tests, screening solutions, and information. The Legacy Sema4 diagnostics segment provides reproductive and women's health and somatic oncology diagnostic testing and screening products.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
28 USD
Average target price
23.12 USD
Spread / Average Target
-17.41%
Consensus
  1. Stock Market
  2. Equities
  3. WGS Stock
  4. News GeneDx Holdings Corp.
  5. BTIG Adjusts Price Target on GeneDx Holdings to $35 From $19, Maintains Buy Rating